

- **Full Name:** Jo A. Van Ginderachter
 - **Current Position & Affiliation:** Professor Immunology at Vrije Universiteit Brussel, Group Leader at VIB, Brussels, Belgium
 - **Country:** Belgium
-

• Educational Background:

- 1995: MSc in Bioengineering Sciences, Vrije Universiteit Brussel, Brussels, Belgium
- 2002: PhD in Applied Biological Sciences, Vrije Universiteit Brussel, Brussels, Belgium

• Professional Experience:**October 2002 - December 2003 :**

- 50% post-doctoral researcher, Lab of Cellular and Molecular Immunology, Dept of Molecular and Cellular Interactions, VIB-Vrije Universiteit Brussel.
- 50% Research & Development coordinator of the VIB Department of Molecular and Cellular Interactions, Vrije Universiteit Brussel

January 2004 - December 2006 :

- Post-doctoral researcher, supported by a competitive post-doctoral “Prospective Research for Brussels” grant, granted by the Brussels region (Innoviris). Lab of Cellular and Molecular Immunology, Dept of Molecular and Cellular Interactions, VIB-Vrije Universiteit Brussel.

January 2007 – December 2010 :

- Staff Scientist, Dept of Molecular and Cellular Interactions, VIB-Vrije Universiteit Brussel, supported by a Stichting tegen Kanker research grant.

October 2010 – September 2014:

- 10% Zelfstandig Academisch Personeel (Assistant Professor), Faculty of Sciences and Bio-engineering Sciences. (research theme: Mechanisms of tumor growth mediated by tumor-host interactions)
- Principal Investigator in the lab of Cellular and Molecular Immunology, Dept of Molecular and Cellular Interactions, VIB

From October 2012 onward :

- Group Leader, Myeloid Cell Immunology Lab, VIB, Brussels, Belgium

From October 2014 onward :

- Appointed as full time lecturer and professor (Tenure Track) at Vrije Universiteit Brussel, Brussels, Belgium.
- Program director of the MSc in Biomolecular Sciences, Faculty of Sciences and Bio-engineering Sciences

From October 2019 onward :

- Tenured professor Immunology at Vrije Universiteit Brussel, Brussels, Belgium

Research stays and guest lecturer :

- **May-June 1998** : lab of Prof. Dr. Lea Eisenbach, Weizmann Institute, Rehovot, Israël.
- **September-October 2016**: Guest lecturer at the Ghent University Global Campus, Incheon, Korea
- **October-November 2016**: Guest lecturer at the Universidade de Sao Paulo (USP), Brazil
- **Easter holidays 2017**: Guest lecturer at the Universidade de Sao Paulo (USP), Brazil
- **July 2017**: Guest lecturer at the Universidade de Sao Paulo (USP), Brazil

• Professional Organizations:

- Board member, Belgian Immunological Society
- Board member, Belgian Association for Cancer Research
- Board of Directors member, Flanders Vaccine
- Faculty Council member, faculty of Sciences and Bio-engineering Sciences, Vrije Universiteit Brussel
- Educational Commission member, faculty of Sciences and Bio-engineering Sciences, Vrije Universiteit Brussel
- Educational Board member and co-founder, Master of Science in Molecular Biology, Vrije Universiteit Brussel
- Co-founder of the VUB spin-off company Abscint, employing Nanobodies for non-invasive molecular imaging
- Editorial Board member, Cancer Research
- Editorial board member, Frontiers in Immunology

• Main Scientific Publications:

1. Pombo Antunes AR,..., **Van Ginderachter JA**[#], Movahedi K[#]. ([#] shared co-senior). Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. *Nature Neuroscience*, 24(4):595-610, 2021. IF=20.071; CIT=156
2. Van Damme H,..., Laoui D, **Van Ginderachter JA**. Therapeutic depletion of CCR8⁺ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. *Journal for Immunotherapy of Cancer*, 9(2):e001749, 2021. IF=10.252; CIT=41
3. Laoui D, Keirse J,..., **Van Ginderachter JA**. The tumor microenvironment harbors ontogenically distinct dendritic cell populations with opposing effects on tumor immunity. *Nature Communications*, 7:13720, 2016. IF=11.329; CIT=165
4. Laoui D, Van Overmeire E,..., **Van Ginderachter JA**. Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. *Cancer Research*, 74(1):24-30, 2014. IF=9.55; CIT=291
5. Movahedi K,..., **Van Ginderachter JA**. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Research*, 70: 5728-5739, 2010. IF=7.543; CIT=833.

6. Movahedi K,...,**Van Ginderachter JA**. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. *Blood*,111(8): 4233-4244,2008. IF=10.432; CIT=934